Cardiovascular Systems Stock News

Equities research analysts predict that Cardiovascular Systems, Inc. (NASDAQ:CSII) will announce earnings of ($0.14) per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Cardiovascular Systems earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.09). The company is scheduled to []

Cardiovascular Systems, Inc. (NASDAQ:CSII) has been assigned an average recommendation of Hold from the nine research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 1 []

Cardiovascular Systems, Inc. (NASDAQ:CSII) saw unusually-strong trading volume on Thursday . Approximately 31,844 shares were traded during trading, a decline of 86% from the previous sessions volume of 230,275 shares.The stock last traded at $19.33 and had previously closed at $20.00. A number of equities research analysts have issued reports on CSII shares. SVB Leerink []

Cardiovascular Systems Inc. (NASDAQ:CSII) has a beta value of 0.86 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $855.60M, closed the last trade at $20.00 per share which meant it lost -$1.11 on the day or -5.26% during that session. The CSII stock price is -141.4% Cardiovascular Systems Inc. (CSII) Has Great Growth Outlook For 2021 Read More »

Cardiovascular Systems, Inc. (NASDAQ:CSII)s stock price traded down 5.2% during trading on Monday . The stock traded as low as $21.91 and last traded at $22.04. 3,588 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 224,533 shares. The stock had previously closed at $23.26. Several equities analysts []

Cardiovascular Systems Inc (NASDAQ: CSII ) has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION). The unused WRN-D6 models of the WIRION device are being recalled due to receiving complaints regarding filter breakage at the time of retrieval. The Company stated that the filter breakage might cause device embolism as well as additional intervention. All affected healthcare facilities were informed Full story available on Benzinga.com

Cardiovascular Systems Inc (NASDAQ: CSII) has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION). The unused WRN-D6 models of the WIRION device are being recalled due to

Several analysts have recently updated their ratings and price targets for Cardiovascular Systems (NASDAQ: CSII): 11/17/2021 Cardiovascular Systems was downgraded by analysts at Needham & Company LLC from a buy rating to a hold rating. 11/12/2021 Cardiovascular Systems was downgraded by analysts at Zacks Investment Research from a hold rating to a strong []

Cardiovascular Systems Inc. (NASDAQ:CSII) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.86% to the previous days close as strong demand from buyers drove the stock to $23.72. Actively observing the price movement in the last trading, the stock closed the session at $23.06, falling within a range of $22.6316 Cardiovascular Systems Inc. (NASDAQ:CSII) Will Likely Reach 40.00 USD! Read More »

Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

Metropolitan Life Insurance Co NY raised its holdings in shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) by 106,381.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 11,713 shares of the medical device companys stock after purchasing an additional 11,702 shares during the quarter. Metropolitan Life Insurance Co NYs holdings in Cardiovascular Systems were worth $500,000 []

Equities research analysts predict that Cardiovascular Systems, Inc. (NASDAQ:CSII) will announce sales of $62.71 million for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Cardiovascular Systems earnings, with estimates ranging from $61.30 million to $66.30 million. Cardiovascular Systems reported sales of $64.17 million in the same quarter last year, []

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.